A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients (Single Dose Study)
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2019
Price : $35 *
At a glance
- Drugs MT-2990 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 22 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2018 Status changed from not yet recruiting to recruiting.